Patients with Philadelphia positive (Ph + ) adult acute lymphoblastic leukaemia (ALL) have a poor prognosis. Stem cell transplantation (SCT) is increasingly being recognised as the treatment of choice in eligible patients with Ph + ALL, but disease-relapse remains a problem in a proportion of patients prior to and after SCT. Genetic abnormalities in addition to the Ph chromosome may influence the biology and clinical course of ALL, but there are not many studies on the potential genetic heterogeneity of adult Ph + ALL and clinical outcomes. Here, we report on five patients with ALL who were double Ph + and also had a high-hyperdiploid karyotype (Ph + / hyperdiploid) at diagnosis. In contrast to the presence of the Ph + chromosome, high-hyperdiploidy (450 chromosomes) as the sole karyotypic abnormality in ALL is associated with a favourable clinical outcome. In our series, four patients with a Ph + /hyperdiploid karyotype achieved a cytogenetic remission after induction chemotherapy and proceeded to stem cell transplantation (SCT). The fifth had five subclones including Ph + / hyperdiploid, as well as those that were only Ph + ; the latter emerged as the dominant clone after induction therapy and the patient died of disease-relapse. Of the patients who underwent SCT, only one relapsed, but achieved a durable remission with donor lymphocyte infusions. Thus, it is conceivable that the presence of high-hyperdiploidy as an additional karyotypic abnormality may confer a better prognosis to 1 Hence consolidative therapy with stem cell transplantation (SCT) is increasingly being recommended for these high-risk patients with ALL, 2 but early results from some studies have not indicated an improvement in disease-free survival even with SCT. 3 Attempts have therefore been made to identify factors predicting disease recurrence before and after SCT, and these have suggested that the ability to detect minimal residual disease (bcr-abl) by RT-PCR may predict relapse post-SCT. 4 While the ability to detect bcr-abl undoubtedly indicates continuing presence of leukaemic cells, it does not explain the apparent refractoriness to treatment. It is conceivable that the simultaneous presence of additional karyotypic abnormalities may alter the biological properties of Ph + cells and influence clinical outcomes. In this context, the coexistence of a high-hyperdiploid (450 chromosomes) karyotype with the Ph + chromosome (Ph + /hyperdiploid) is of interest since high-hyperdiploidy as the sole cytogenetic abnormality in ALL is associated with a good prognosis, especially in children. 5 Here we report on the outcomes of five adults with ALL who had a Ph + /hyperdiploid karyotype and attempt to determine whether the adverse prognosis conferred by Ph + may be altered by the presence of cytogenetic predictors of good response.
Patients

Diagnosis
The outcomes of all patients with Ph + ALL/hyperdiploid karyotype in our institution since 1995, with intention to treat by SCT were studied. There were two males and three females with a median age of 34 years (range 22-52). Patient characteristics including karyotype at diagnosis are shown in Table 1 . All patients had a high-hyperdiploid karyotype (450 chromosomes) and a double Ph chromosome. In one patient, four abnormal subclones were identified, of which two contained the double Ph + / hyperdiploid karyotype. Immunophenotype of blasts was consistent with common ALL (cALL). Assays to detect the bcr/abl gene rearrangement by RT-PCR or FISH were not performed routinely in these patients at diagnosis, although patients Nos. 2, 4 and 5 were all shown to have a RT-PCR transcript consistent with a p190 bcr/abl protein.
Induction treatment and response
Patients were treated in the context of the Medical Research Council (MRC), UK led multicentre clinical trials and had been randomised to receive allogeneic SCT. All but one patient achieved a cytogenetic remission after induction chemotherapy, although, in this patient (No. 5), the Ph + /hyperdiploid clones were no longer detectable on days 22 and 36 of phase I induction therapy. Karyotype analysis on these 2 days revealed the continuing presence of one and two of the original subclones, respectively:
Day 22
45, XX,add (3) (q12), t(9;22) (q34;q11), -11,add (16) This patient developed florid haematological relapse just prior to conditioning for the transplant and died. Marrow analysis 5 months after start of treatment (prior to haematological relapse) had shown persistence or reemergence of one of the original clones: 46, XX, t(9;22) (q34;q11) [1] /46, XX [29] , with no evidence of the hyperdiploid clone present at diagnosis.
SCT and response
Four patients proceeded to SCT within a median of 5.5 months post-diagnosis (range 4-7 months). One patient (No. 8) was treated with an autograft since a suitable unrelated donor was unavailable. Details of SCT, including conditioning are shown in Table 2 . For prophylaxis against central nervous system disease, patients were treated with 5.4 Gy of cranial radiotherapy (in three divided doses) or intrathecal methotrexate (12.5 mg/dose). Short-course methotrexate and cyclosporin were used for graft-versushost disease (GvHD) prophylaxis in patients receiving allografts.
Recovery of neutrophil and platelet counts was as expected (Table 2 ) and there was no graft failure. Two patients receiving allografts developed acute GvHD and one (No. 3) required treatment with intravenous methylprednisolone. This patient developed further Grade 2 GvHD (skin and gut) on cyclosporin taper. Following another attempt at taper, he developed Grade 3 GvHD (liver) 9 months post-SCT. GvHD was refractory to intravenous steroids, but responded to azathioprine and CAMPATH IG (10 mg/day for 5 days).
Disease status in marrow was investigated serially in all patients receiving an allograft by marrow morphology, immunophenotyping and BCR-ABL transcripts routinely after 90 and 180 days, unless a more frequent analysis was indicated. Blood counts were monitored periodically in patient No. 8 since she declined marrow aspiration. One patient (No. 2) suffered a haematological relapse 5 months after SCT with a hyperdiploid karyotype similar to that at diagnosis: 54; XX; þX; þ2; addð2Þðp1Þ; þ4; þ5; þ6; tð9; 22Þ Â ðq34; q11Þ; þ11; þ21; þderð22Þtð9; 22Þ½16=46; XX½4
Following treatment with a combination of vincristine, oral prednisolone and 6-mercaptopurine, she achieved a haematological remission. Thereafter, she received escalating dose donor lymphocye infusions (DLI): two courses of DLI with 1 and 10 Â 10 6 CD3 + cells/kg on days +20 and +64 postrelapse, respectively. No residual disease was detected on follow-up studies (22 months post-SCT) by RT-PCR. However, 32 days after the second dose of DLI, she developed liver GvHD (alkaline phosphatase 1104, range 70-260 U/l; bilirubin 110, range 1-22 mmol/l and aspartate transaminase 74, range 5-43 U/l), requiring treatment with intravenous methylprednisolone. Liver function normalised within 36 days of steroid therapy. At a median follow-up of 51.5 months postdiagnosis (range 26-88 months), all patients who underwent SCT are alive and in remission. 
Discussion
The prognosis for adult Ph + ALL is poor although certain patients may benefit from SCT. 2 We have attempted to determine whether favourable results with SCT in some patients with Ph + ALL may be influenced by the presence of additional chromosomal abnormalities and have studied the outcomes of five adults with Ph + ALL who had a highhyperdiploid karyotype in addition to duplication of the Ph + chromosome. High-hyperdiploidy in ALL has a distinct nonrandom pattern, with gain of chromosomes X, 4, 6, 14 and 21 being most frequently observed. 6 The high-hyperdiploid pattern in our patients showed similar patterns of chromosome gain. High-hyperdiploid ALL blasts are known to have a marked propensity for apoptosis in vitro, which has been linked to the relatively good in vivo response to chemotherapy. 7 In contrast, the presence of a double Ph + chromosome has been associated with shorter disease-free and overall survival in ALL. 8 A disease-response (cytogenetic remission) was observed in all our patients after induction therapy, except in one patient with multiple subclones at diagnosis. Even in this patient, however, Ph + /hyperdiploid clones were undetectable following induction chemotherapy, and disease relapse appeared to originate from subclones that were Ph + , but not hyperdiploid. These results are similar to those reported by Rieder et al 9 , who detected high hyperdiploidy in up to 17% of adults with Ph + ALL. In their series, patients with the Ph + /hyperdiploid karyotype achieved complete remission more readily than patients who did not have an additional hyperdiploid karyotype, although the duration of remission and overall survival was similar in the two groups. Relapse in the Ph + / hyperdiploid patients in their series also appeared to be mediated by the presence of subclones at diagnosis, some of which contained Ph + as the sole abnormality. ALL patients in the CALGB study on the significance of karyotype in ALL. 13 However, in the recently published prospective multicentre LALA-94 trial, 14 12 out of 91 patients with Ph + ALL and coexisting chromosomal anomalies had a hyperdiploid karyotype. Results of this study have indicated that hyperdiploidy is associated with an increased rate of molecular remissions after consolidation therapy. Owing to small numbers of patients, subgroup analysis after SCT was not feasible. Table 2 Details of induction treatment, cytogenetic status and transplant regime for patients with Ph + ALL treated with SCT (T x ). Post-T x events including time (in days post-SCT) to neutrophil (n) and platelet (Plt) engraftment, acute (Ac) and chronic (ch) GVHD are also described 17 and identify prognostic subgroups within Ph + ALL based on the presence of cytogenetic abnormalities. Such an approach may identify patients who could benefit from newer therapeutic approaches.
